Two Sigma Advisers LP Lowers Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Two Sigma Advisers LP reduced its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 33.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 199,300 shares of the company's stock after selling 98,400 shares during the period. Two Sigma Advisers LP owned approximately 0.14% of MiMedx Group worth $1,917,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. First Light Asset Management LLC purchased a new stake in shares of MiMedx Group during the 4th quarter valued at $32,168,000. Norges Bank purchased a new stake in shares of MiMedx Group during the 4th quarter valued at $4,020,000. JPMorgan Chase & Co. increased its holdings in MiMedx Group by 133.1% in the 4th quarter. JPMorgan Chase & Co. now owns 693,106 shares of the company's stock worth $6,668,000 after acquiring an additional 395,739 shares during the last quarter. Meros Investment Management LP purchased a new stake in MiMedx Group in the 4th quarter worth about $3,801,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in MiMedx Group by 484.2% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 362,481 shares of the company's stock worth $3,487,000 after acquiring an additional 300,433 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on MDXG. Wall Street Zen lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, May 9th. Cantor Fitzgerald reiterated an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

MiMedx Group Trading Up 1.4%

MDXG stock traded up $0.09 on Tuesday, reaching $6.48. The company's stock had a trading volume of 475,866 shares, compared to its average volume of 690,011. The business has a fifty day simple moving average of $6.89 and a two-hundred day simple moving average of $8.10. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The firm has a market cap of $957.11 million, a PE ratio of 11.78 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, meeting the consensus estimate of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. As a group, research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insiders Place Their Bets

In other news, CAO William Frank Iv Hulse sold 54,596 shares of the business's stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total value of $430,762.44. Following the completion of the transaction, the chief accounting officer now directly owns 440,178 shares of the company's stock, valued at approximately $3,473,004.42. The trade was a 11.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction that occurred on Friday, May 2nd. The shares were acquired at an average cost of $6.34 per share, for a total transaction of $1,268,000.00. Following the completion of the transaction, the chief executive officer now directly owns 529,530 shares in the company, valued at $3,357,220.20. This represents a 60.69% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 141,907 shares of company stock valued at $1,112,580 in the last quarter. 1.70% of the stock is currently owned by insiders.

MiMedx Group Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.